Table 1:
Baseline demographics, disease characteristics, and treatment history.
| Patient Age Groups | |||
|---|---|---|---|
| Factor | < 65 yrs (N=78) | ≥ 65 yrs (N=39) | p-value |
| Age biologic | 37.6±13.5 | 69.6±3.5 | <0.001 |
| Disease duration | 13.3±7.9 | 20.6±10.7 | 0.011 |
| Female | 41(52.6) | 17(43.6) | 0.36 |
| Smoker | 0.005 | ||
| Never | 55(70.5) | 26(66.7) | |
| Current | 12(15.4) | 0(0.0) | |
| Former | 11(14.1) | 13(33.3) | |
| Hospitalization within 1 year | 44(56.4) | 14(35.9) | 0.037 |
| Age, Montreal | <0.001 | ||
| <16 year | 25(32.1) | 3(7.7) | |
| 17–40 year | 43(55.1) | 11(28.2) | |
| >40 year | 10(12.8) | 25(64.1) | |
| Location, Montreal | <0.001 | ||
| Ileal | 7(9.0) | 2(5.1) | |
| Colonic | 3(3.8) | 11(28.2) | |
| Ileo-colonic | 68(87.2) | 26(66.7) | |
| Behaviour, Montreal | 0.014 | ||
| Non-stricturing, non-penetrating | 21(26.9) | 5(12.8) | |
| Stricturing | 42(53.8) | 17(43.6) | |
| Penetrating | 15(19.2) | 17(43.6) | |
| Perianal Involvement | 26(33.3) | 4(10.3) | 0.007 |
| Disease severity per PGA* | 0.001 | ||
| Mild | 2(2.6) | 0(0.0) | |
| Moderate | 41(52.6) | 34(87.2) | |
| Severe | 35(44.9) | 5(12.8) | |
| Endoscopic severity | 0.25 | ||
| Mild | 3(4.6) | 4(13.8) | |
| Moderate | 33(50.8) | 15(51.7) | |
| Severe | 29(44.6) | 10(34.5) | |
| Prior surgery | 0.26 | ||
| Never | 21(27.6) | 10(26.3) | |
| Within 1year | 26(34.2) | 8(21.1) | |
| >1 year | 29(38.2) | 20(52.6) | |
| Type of surgery | 0.12 | ||
| Colectomy | 5(8.2) | 6(21.4) | |
| Ileo-colonic resection | 13(21.3) | 8(28.6) | |
| Segment small bowel resect | 4(6.6) | 4(14.3) | |
| Abscess drain | 3(4.9) | 0(0.0) | |
| Multiple | 31(50.8) | 10(35.7) | |
| Baseline Steroids | 0.31 | ||
| Never Used | 6(7.7) | 1(2.6) | |
| Former Use | 37(47.4) | 22(56.4) | |
| Steroid responsive | 30(38.5) | 16(41.0) | |
| Steroid-refractory | 5(6.4) | 0(0.0) | |
| Baseline Thiopurine | 0.36 | ||
| Never Used | 26(33.3) | 18(46.2) | |
| Current Use | 11(14.1) | 2(5.1) | |
| Former - 6-MP or AZA use | 41(52.6) | 19(48.7) | |
| Prior Biologic use | 77(98.7) | 37(94.9) | 0.26 |
| Biologic type | <0. 001 | ||
| Infliximab | 27 (33.3) | 9 (23.1) | |
| Adalimumab | 27(33.3) | 11 (28.2) | |
| Golimumab | 8 (9.9) | 12 (30.8) | |
| Certolizumab | 12 (14.8) | 4 (10.3) | |
| Vedolizumab | 7 (8.6) | 0 (0) | |
| Total number of biologics/patient | 2.3±1.00 | 2.1±1.4 | 0.23 |
| Baseline Steroids | 37(49.3) | 20(51.3) | 0.84 |
| Steroid dose (mg)1 | 22.6±14.8 | 26.5±11.8 | 0.30 |
*
PGA= Physician global assessment Statistics presented as Mean ± SD, Median [P25, P75], Median (min, max) or N (column %).
Bold indicates significant p-value <0.05. 1: Prednisone equivalent